7 terminated. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 7 |
Follow Peritoneal Diseases: new trials by email Literature Review of Peritoneal Diseases trials Research Report on Peritoneal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer AB-1015 - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 1 | Terminated | Arsenal Biosciences, Inc. | 19 | 2022-11-29 | 2026-10-29 |
| Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis Paclitaxel-loaded tumor penetrating microparticles - Peritoneal Carcinomatosis | Phase 1 | Terminated | Carlos Chan | 4 | 2022-04-26 | 2026-02-25 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors Felmetatug Vedotin, Pembrolizumab - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 250 | 2022-01-12 | 2026-01-09 |
| Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis Intraperitoneal docetaxel - Peritoneal Carcinomatosis | Phase 1 | Terminated | Johns Hopkins University | 2 | 2020-11-01 | 2024-08-09 |
| A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis SCB-313 - Peritoneal Carcinomatosis | Phase 1 | Terminated | Sichuan Clover Biopharmaceuticals, Inc. | 10 | 2019-09-10 | 2023-04-12 |
| The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients Tissue Plasminogen Activator (tPA), recombinant deoxyribonuclease (DNase) - Peritoneal Dialysis, Peritoneal Dialysis, Continuous Ambulatory | Phase 1 | Terminated | Sir Charles Gairdner Hospital | 5 | 2016-01-01 | 2022-05-19 |
| ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma ABI-007, Carboplatin - Fallopian Tube Neoplasms, Peritoneal Neoplasms | Phase 1 | Terminated | Celgene | 6 | 2006-11-01 | 2019-10-18 |
Peritoneal Neoplasms (6) · Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Abdominal Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Genital Neoplasms, Female (1) · Neoplasms, Glandular and Epithelial (1) · Ovarian Diseases (1) · Peritonitis (1) · Recurrence (1)
Digestive System Diseases (7) · Digestive System Neoplasms (6) · Neoplasms (6) · Neoplasms by Site (6) · Abdominal Neoplasms (5) · Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Fallopian Tube Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Gonadal Disorders (3)
Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Cell Count (1) · Docetaxel (1) · Tissue Plasminogen Activator (1) · dornase alfa (1) · pembrolizumab (1)
Arsenal Biosciences, Inc. (1) · Carlos Chan (1) · Celgene (1) · Johns Hopkins University (1) · Seagen, a wholly owned subsidiary of Pfizer (1) · Sichuan Clover Biopharmaceuticals, Inc. (1) · Sir Charles Gairdner Hospital (1)
United States (5) · Australia (1) · Canada (1) · China (1) · Germany (1) · Spain (1) · United Kingdom (1)
Aron Chakera, DPhil (1) · Arsenal Biosciences (1) · Carlos Chan, MD, PhD (1) · Fabian M Johnston, MD, MHS (1) · Robert Coleman, MD (1)
2023 (1)